An illustration of the usefulness of the multi-state model survival analysis approach for health economic evaluation modelling

Abstract: This seminar will demonstrate the potential of multi-state survival modeling (MSM) as a tool for decision analytic modelling and compare it to the usual Markov transition modelling approach. After briefly reviewing examples of MSM in the health economics literature, a technology appraisal submitted to NICE evaluating the cost effectiveness of Rituximab for first line treatment of chronic lymphocytic leukaemia will be used for illustration purposes. Finally, areas of future research will be outlined.